Khoo Ai Leng, Teng Monica, Lim Boon Peng, Tai Hwei Yee, Lau Tang Ching
Pharmacy and Therapeutics Office, National Healthcare Group, Singapore.
Jt Comm J Qual Patient Saf. 2013 May;39(5):205-12. doi: 10.1016/s1553-7250(13)39027-8.
High-alert medications can cause significant patient harm when used in error. A multicenter, multidisciplinary, high-alert medication collaborative was established in Singapore in 2009 to identify and maintain a current list of high-alert medications and to create systematic approaches for preventing and reducing the risk of medication errors and adverse drug events (ADEs) for high-alert medications.
The collaborative was led by a core multidisciplinary team consisting of pharmacists, nurses, and physicians, as well as clinical services and quality personnel, from six primary and acute care institutions. Multidisciplinary work groups were formed to drive the improvement efforts using the Plan-Do-Study-Act (PDSA) cycles. Tracking of improvement work was conducted with an adaptation of the Institute for Healthcare Improvement Trigger Tool method.
A localized high-alert medication list was developed through local ADE reports, literature review, an online survey of health care professionals, and expert opinion. Some 130 interventions were proposed to prevent, detect, and mitigate harm from the use of high-alert medications for 10 drug classes/drugs. A significant number of these interventions were tested and revised during the PDSA cycles before implementation throughout the institution and subsequent spread to other institutions. Outcome audits identified areas for improvement. The interventions, which were subsequently incorporated into the change packages, led to a 50% and 67% decline in the ADE rates for radiocontrast agents and heparin, respectively.
The collaborative has provided a sound framework for ongoing development and refinement of high-alert medication change packages and for sharing of ADE data and best practices across the participating institutions.
高警示药品一旦使用错误,可能对患者造成严重伤害。2009年,新加坡成立了一个多中心、多学科的高警示药品协作组织,以确定并更新高警示药品清单,并制定系统方法,预防和降低高警示药品用药错误及药物不良事件(ADEs)的风险。
该协作组织由一个核心多学科团队牵头,团队成员包括来自六家基层和急症护理机构的药剂师、护士、医生以及临床服务和质量管理人员。成立了多学科工作组,采用计划-实施-研究-改进(PDSA)循环推动改进工作。采用医疗改进研究所触发工具方法的改编版对改进工作进行跟踪。
通过本地ADE报告、文献综述、对医疗保健专业人员的在线调查以及专家意见,制定了一份本地化的高警示药品清单。针对10类药物/药品,提出了约130项干预措施,以预防、发现并减轻高警示药品使用造成的伤害。在PDSA循环期间,对其中大量干预措施进行了测试和修订,然后在整个机构实施,并随后推广到其他机构。结果审计确定了需要改进的领域。这些干预措施随后被纳入变更包,使放射造影剂和肝素的ADE发生率分别下降了50%和67%。
该协作组织为持续开发和完善高警示药品变更包,以及在参与机构之间共享ADE数据和最佳实践提供了一个良好的框架。